Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Zhaoke Ophthalmology Ltd. ( (HK:6622) ) is now available.
Zhaoke Ophthalmology has announced that Australia’s Therapeutic Goods Administration has accepted for evaluation its registration application for Atropine Sulfate Eye Drops (0.01% NVK002), an investigational treatment aimed at controlling myopia progression in children. The application, supported by positive Phase III clinical trial data, marks a significant regulatory milestone for one of the world’s most advanced low-dose atropine candidates, which features a preservative-free, globally patented formulation with a shelf life exceeding 24 months and targets a broad age range of 3 to 17 years, potentially strengthening the company’s position in the global pediatric myopia treatment market if ultimately approved and commercialized.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a specialty ophthalmic pharmaceutical company focused on developing and commercializing innovative eye treatments, with a particular emphasis on therapies for conditions such as myopia in children and adolescents. The company leverages proprietary formulations and globally protected intellectual property to address unmet needs in ophthalmology across major markets, including the Asia-Pacific region.
Average Trading Volume: 964,878
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.85B
For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.